-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S7VLbj178SILkYCcWhnnBoJ/ZzHgwefLXmaI/bNylNpj9r1WzOwcr8PI6esbVE7/ ft4j7IfZRLmke1H2mzgj4A== 0000893220-97-001937.txt : 19971216 0000893220-97-001937.hdr.sgml : 19971216 ACCESSION NUMBER: 0000893220-97-001937 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19971215 SROS: NONE GROUP MEMBERS: SMITHKLINE BEECHAM PLC GROUP MEMBERS: SR ONE LTD. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: SEC FILE NUMBER: 005-44877 FILM NUMBER: 97738530 BUSINESS ADDRESS: STREET 1: 420 CHIPETA WAY SUITE 240 CITY: SALT LAKE CITY STATE: UT ZIP: 84108-1256 BUSINESS PHONE: 8015834939 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SMITHKLINE BEECHAM PLC CENTRAL INDEX KEY: 0000850695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980101920 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: ONE NEW HORIZONS COURT STREET 2: BRENTFORD MIDDLESEX CITY: TW8 9EP ENGLAND STATE: X0 MAIL ADDRESS: STREET 1: SMITHKLENE BEECHAM STREET 2: ONE FRANKLIN PLAZA CITY: PHILADELPHIA STATE: PA ZIP: 19101 SC 13D 1 NPS PHARMACEUTICALS, INC. SCHEDULE 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 NPS Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.001 Par Value - -------------------------------------------------------------------------------- (Title of Class of Securities) 62936P103 - -------------------------------------------------------------------------------- (CUSIP Number) Donald F. Parman, SmithKline Beecham Corporation One Franklin Plaza, Philadelphia, PA 19102 Telephone 215-751-7633 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 5, 1997 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 62936P103 PAGE 2 OF 7 PAGES - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SmithKline Beecham plc 98-010920 - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /x/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION England - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 160,000 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 160,000 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 160,000 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.3% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 3 SCHEDULE 13D CUSIP NO. 62936P103 PAGE 3 OF 7 PAGES - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON S.R. One, Limited 23-1729901 - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /x/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Pennsylvania Business Trust - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 1,163,801 (Including 5,700 stock options) BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 1,163,801 (Including 5,700 stock options) ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,163,801 (Including 6,500 stock options) - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.6% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 4 Page 4 of 7 Pages Item 1. Security and Issuer. Common Stock, $.001 Par Value NPS Pharmaceuticals, Inc. 420 Chipeta Way, Suite 240 Salt Lake City, UT 84108-1256 Item 2. Identity and Background. (a) S.R. One, Limited ("SRO"), a Pennsylvania business trust, is a venture capital company. SmithKline Beecham plc ("SBplc"), a company organized under the laws of England, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related products, and the provision of healthcare services including clinical laboratory testing, disease management, and pharmaceutical benefit management. Collectively, SRO and SBplc are sometimes referred to as the "Group". (b) The principal business address for SRO is: 565 East Swedesford Road Suite 315 Wayne, Pennsylvania 19087 The principal business address for SBplc is: New Horizons Court Brentford Middlesex ENGLAND TW8 9EP (c) Information concerning the Group is set forth in response to Item 2(a) above. (d) During the last five years, the Group has not been convicted in a criminal proceeding, excluding traffic violations or similar misdemeanors. (e) During the last five years the Group was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result thereof subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to Federal or State securities laws or finding any violation with respect to such laws. (f) Not applicable. Item 3. Source and Amount of Funds or Other Consideration. Source of Funds: Working Capital Consideration: $1,954,000 Item 4. Purpose of Transaction. The Group intends to review from time to time the business affairs and financial position of the Issuer. Based on such evaluation and review, as well as general economic and industry conditions existing at the time and the Group's own financial plans, the Group may consider from time to time various alternative courses of action. Such actions may include the acquisition of additional shares through open market purposes, privately negotiated transactions or otherwise. Alternatively, such actions may involve the sale of all or a portion of the shares in the open market, in privately negotiated transactions, through public offering or otherwise. All of the securities acquired have been purchases for investment purposes. 5 Page 5 of 7 Pages Item 5. Interest in Securities of the Issuer. (a) Amount and Percent Beneficially Owned
Reporting Person No. of Shares Percent SRO 1,163,801(1) 9.6% SBplc 160,000 1.3% --- 10.9%
(1) Includes 5,700 shares which SRO has right to acquire by exercise of stock options. (b) The respective members of the Group have sole power to vote and to dispose of all of the shares of Common Stock identified in subparagraph (a) above, except for the shares covered by stock options as set for in note (1) thereto. In the event of the purchase of such shares, SRO would have the sole power to vote and dispose of all the shares of Common Stock issued upon such purchase. Until such purchase SRO has no sole or shared power to vote or dispose of any of the stock options. (c) In connection with the Issuer's initial public offering ("IPO") in May 1994, SRO received 1,701,301 shares of Common Stock upon conversion of Preferred Stock purchased by SRO prior to the IPO. In June 1994, SRO purchased an additional 90,000 shares at $5.50 per share. Director stock options with repect to 5,700 shares of Common Stock granted to SRO's representative on the Issuer's Board of Directors have been transferred to SRO and have not yet been exercised. In addition, 1,800 shares of Common Stock granted to SRO's representative as consideration for Board service have been transferred to SRO. In December 1996, SRO sold 505,000 shares through open market transactions at an average price of $9.87 per share. On December 5, 1997, SBplc purchased 160,000 shares of Common Stock in a private placement at $12.2125 per share. SRO sold 130,000 shares of Common Stock in the open market in the following manner:
Registered Name Transaction Date No. of Shares Price Per Share S.R. One, Limited 12-05-97 20,000 $ 9.5313 S.R. One, Limited 12-10-97 60,000 $ 8.25 S.R. One, Limited 12-11-97 50,000 $ 8.25
(d) The only transactions involving the Group and the Common Stock of the Issuer are the transactions referenced above. (e) Not applicable Item 6. Contracts, Arrangements, Understandings or Relationship With respect to Securities of the Issuer. None Item 7. Materials to be Filed as Exhibits. Exhibit 1. Joint Filing Agreement dated as of December 12, 1997. 6 Page 6 of 7 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in the Statement is true, correct and complete. DATED: December 15, 1997 ------------------------------ 7 Page 7 of 7 Pages EXHIBIT 1 The undersigned hereby agree, pursuant to Rule 13d-1(f)(1) under Section 13(d) of the Securities Exchange Act of 1934, as amended, that (1) they shall cause a single Schedule 13D to be filed on behalf of both parties in respect of their ownership interests in the Common Stock of NPS Pharmaceuticals, Inc. and (2) S.R. One, Limited shall be authorized to sign said Schedule 13D and any amendments thereto on behalf of both members of the Group. S.R. ONE, LIMITED By: /s/ Donald F. Parman -------------------- Donald F. Parman Vice President and Secretary SMITHKLINE BEECHAM plc By: /s/ Alison Dillon ------------- Alison Dillon Deputy Secretary DATED: December 15, 1997 -----END PRIVACY-ENHANCED MESSAGE-----